Latus Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $97M

  • Investors
  • 13

Latus General Information

Description

Developer of gene therapy technology designed to treat central nervous system and peripheral disorders through precision delivery of novel AAV capsid variants. The company's platform utilizes advanced computational methods and unbiased high-throughput screening to mine a proprietary database of unique delivery sequences, identifying AAV capsid variants matched to optimized routes of administration for cell-specific targeting with minimal off-tissue distribution, reduced dose requirements at fractions of conventional levels, and lower cost of goods, enabling healthcare providers and researchers focused on monogenic diseases to access safer and more cost-effective gene therapy treatments.

Contact Information

Website
www.latusbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2929 Arch Street 8th Floor
  • Suite 2
  • Philadelphia, PA 19104
  • United States
+1 (215)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 2929 Arch Street 8th Floor
  • Suite 2
  • Philadelphia, PA 19104
  • United States
+1 (215)

Latus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Latus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 04-May-2026 $97M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A3) 28-Aug-2025 Completed Pre-Clinical Trials
To view Latus’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Latus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene therapy technology designed to treat central nervous system and peripheral disorders through precision
Drug Discovery
Philadelphia, PA
27 As of 2026

Worcester, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Latus Competitors (2)

One of Latus’s 2 competitors is Leal Therapeutics, a Venture Capital-Backed company based in Worcester, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Leal Therapeutics Venture Capital-Backed Worcester, MA
Jaya Biosciences Accelerator/Incubator Backed San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

Latus Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Latus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026178535-A1 Predicting a treatable huntington's disease patient/patient population and effects on disease progression for therapies targeting somatic instability Pending 24-Feb-2025
WO-2026050519-A2 Microrna knockdown of msh3 Pending 28-Aug-2024
WO-2026050519-A3 Microrna knockdown of msh3 Pending 28-Aug-2024 A61K31/7088

Latus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Latus Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Benjamin Franklin Technology Partners Corporation Minority
Calm Ventures Venture Capital Minority
Gaingels Venture Capital Minority
Modi Ventures Venture Capital Minority
Samsung Venture Investment Corporate Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Latus FAQs

  • When was Latus founded?

    Latus was founded in 2022.

  • Where is Latus headquartered?

    Latus is headquartered in Philadelphia, PA.

  • What is the size of Latus?

    Latus has 27 total employees.

  • What industry is Latus in?

    Latus’s primary industry is Drug Discovery.

  • Is Latus a private or public company?

    Latus is a Private company.

  • What is Latus’s current revenue?

    The current revenue for Latus is .

  • How much funding has Latus raised over time?

    Latus has raised $131M.

  • Who are Latus’s investors?

    Benjamin Franklin Technology Partners, Calm Ventures, Gaingels, Modi Ventures, and Samsung Venture Investment are 5 of 13 investors who have invested in Latus.

  • Who are Latus’s competitors?

    Leal Therapeutics and Jaya Biosciences are competitors of Latus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process